273 related articles for article (PubMed ID: 25968563)
1. Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.
Martinez-Martin P; Rodriguez-Blazquez C; Forjaz MJ; Kurtis MM
CNS Drugs; 2015 May; 29(5):397-413. PubMed ID: 25968563
[TBL] [Abstract][Full Text] [Related]
2. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
Gallagher DA; Schrag A
CNS Drugs; 2008; 22(7):563-86. PubMed ID: 18547126
[TBL] [Abstract][Full Text] [Related]
3. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
Deleu D; Northway MG; Hanssens Y
Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
[TBL] [Abstract][Full Text] [Related]
5. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Lew MF; Somogyi M; McCague K; Welsh M;
Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis.
Li T; Zou S; Zhang Z; Liu M; Liang Z
BMC Neurol; 2022 Aug; 22(1):320. PubMed ID: 36008796
[TBL] [Abstract][Full Text] [Related]
7. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
Onofrj M; Thomas A; Vingerhoets F; Martin W; Giménez-Roldán S; Azulay JP; Bernhard G; Schmidt W; Markabi S
J Neural Transm (Vienna); 2004 Aug; 111(8):1053-63. PubMed ID: 15254793
[TBL] [Abstract][Full Text] [Related]
8. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
9. New treatments for levodopa-induced motor complications.
Rascol O; Perez-Lloret S; Ferreira JJ
Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
[TBL] [Abstract][Full Text] [Related]
10. The impact of levodopa on quality of life in patients with Parkinson disease.
Sethi KD
Neurologist; 2010 Mar; 16(2):76-83. PubMed ID: 20220441
[TBL] [Abstract][Full Text] [Related]
11. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
12. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
15. Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety.
Nyholm D
Parkinsonism Relat Disord; 2012 Sep; 18(8):916-29. PubMed ID: 22824056
[TBL] [Abstract][Full Text] [Related]
16. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
[TBL] [Abstract][Full Text] [Related]
17. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.
Faulkner MA
Expert Opin Drug Saf; 2014 Aug; 13(8):1055-69. PubMed ID: 24962891
[TBL] [Abstract][Full Text] [Related]
18. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
19. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
[TBL] [Abstract][Full Text] [Related]
20. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Cattaneo C; Sardina M; Bonizzoni E
J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
